Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Fort Worth, Texas 76134


Randomized, parallel group, subject masked, multi-center six (6) month follow-up study comparing ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 implanted in both eyes to ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL Model SN6AD3 implanted in both eyes.


Inclusion: - Adults, 21 years of age or older at the time of surgery, of either gender or any race, diagnosed with bilateral cataracts - Calculated lens power is within the available range - Willing and able to complete all required postoperative visits - Planned cataract removal by phacoemulsification and/or liquifacture - Potential postoperative visual acuity of 0.2 logMAR or better in study eyes - Preoperative astigmatism of 1.0 Diopter (D) or less, measured by keratometry in study eyes - Clear intraocular media other than cataract in study eyes - Able to comprehend and sign a statement of informed consent - Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR, or if BCDVA is equal to or better than 0.2 logMAR, BCDVA with a Brightness Acuity Tester (BAT) on "Medium" setting must be worse than 0.2 logMAR Exclusion: - Significant irregular corneal aberration as demonstrated by corneal topography - Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level worse than 0.2 logMAR - Subjects who may reasonably be expected to require laser treatments at any time - Previous corneal refractive surgery - Amblyopia - Clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy) - Diabetic retinopathy - Extremely shallow anterior chamber, not due to swollen cataract - Microphthalmos - Previous retinal detachment - Previous corneal transplant - Recurrent severe anterior or posterior segment inflammation of unknown etiology - Rubella or traumatic cataract - Iris neovascularization - Glaucoma (uncontrolled or controlled with medication) - Aniridia - Optic nerve atrophy - Pregnancy - Current or previous usage of an alpha-1-selective adrenoceptor blocking agent or an antagonist of alpha 1A adrenoceptor (e.g.Flomax® (tamsulosin HCL), Hytrin®, or Cardura®) - Any subject currently participating in another investigational drug or device study that may confound the results of this investigation



Primary Contact:


Backup Contact:


Location Contact:

Fort Worth, Texas 76134
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.